Provided by Tiger Trade Technology Pte. Ltd.

Revolution Medicines, Inc.

183.37
-17.5000-8.71%
Volume:1.86M
Turnover:346.93M
Market Cap:39.30B
PE:-20.55
High:199.64
Open:198.51
Low:181.10
Close:200.87
52wk High:224.31
52wk Low:46.16
Shares:214.34M
Float Shares:185.00M
Volume Ratio:3.83
T/O Rate:1.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.9212
EPS(LYR):-5.9502
ROE:-79.09%
ROA:-30.12%
PB:15.08
PE(LYR):-30.82

Loading ...

Revolution Medicines Chief Global Commercialization Officer Anthony Mancini Disposes of Common Shares Worth $347,000

Reuters
·
Sep 23

AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib

GlobeNewswire
·
Sep 22

Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015

GlobeNewswire
·
Sep 22

Nvidia, QIA-Backed Iambic Therapeutics Files for US IPO as Biotech Boom Rolls On

Reuters
·
Sep 22

Revolution Medicines Price Target Raised to $265.00/Share from $225.00 by B of a Securities

Dow Jones
·
Sep 22

BofA Securities Adjusts Revolution Medicines Price Target to $265 From $225, Maintains Buy Rating

MT Newswires Live
·
Sep 21

Revolution Medicines price target raised to $265 from $225 at BofA

TIPRANKS
·
Sep 21

Movement Alert|Revolution Medicines, Inc. Falls 5.1% in Regular Trading, Trading at $194.58

Market Focus
·
Sep 17

Revolution Medicines gets orphan designation for pancreatic cancer treatment

TIPRANKS
·
Sep 16

Analysts Are Bullish on Top Healthcare Stocks: Revolution Medicines (RVMD), ArriVent BioPharma, Inc. (AVBP)

TIPRANKS
·
Sep 15

Revolution Medicines Gets US FDA Breakthrough Therapy Designation for Rasonque To Treat Pancreatic Cancer

MT Newswires Live
·
Sep 15

Revolution Medicines granted Breakthrough Therapy Designation to Rasonque by FDA

TIPRANKS
·
Sep 15

Revolution Medicines Announces U.S. FDA Breakthrough Therapy Designation for Rasonque™ (Daraxonrasib) in Combination with Chemotherapy for First Line Metastatic Pancreatic Cancer

THOMSON REUTERS
·
Sep 15

Analysts Offer Insights on Healthcare Companies: Revolution Medicines (RVMD) and Cooper Co (COO)

TIPRANKS
·
Sep 14

Revolution Medicines Director Lorence H. Kim Disposes of 17,090 Common Shares Worth USD 3.57 Million

Reuters
·
Sep 11

Revolution Medicines Got a 'Miracle' Cancer Drug Approval. Wall Street Wants More.

Dow Jones
·
Sep 11

Revolution Medicines to Gain From Drug Expansion, New Combination Therapies, Morgan Stanley Says

MT Newswires Live
·
Sep 10

Morgan Stanley Initiates Coverage on Revolution Medicines With Overweight Rating

MT Newswires Live
·
Sep 10

Revolution Medicines, Inc. : Morgan Stanley Initiates Coverage with Overweight Rating; Price Target $255

THOMSON REUTERS
·
Sep 10

BeOne Medicines FY26 H1 Net Income Climbs to Us$464.36 Million; Revenue Rises 32.3% to Us$3.22 Billion

Reuters
·
Sep 10